ZYDUS LIFESCIENCES Q2 FY27 CONCALL: REITERATES 24%+ FY27 EBITDA MARGIN & SINGLE-DIGIT US REVENUE GROWTH; TARGETS SAROGLITAZAR US LAUNCH IN MARCH 2027, 8–8.5% R&D SPEND & VACCINE REVENUE DOUBLING IN 3–4 YEARS